Vitamin K: Coagulation and Bone Protein Carboxylation

Core Idea

Vitamin K functions as a cofactor for gamma-carboxylase, an enzyme that carboxylates glutamic acid residues in coagulation factors (II, VII, IX, X) and bone proteins (osteocalcin, matrix Gla protein). This post-translational modification is essential for these proteins to bind calcium and phosphate, enabling proper coagulation cascade function and bone mineralization. Vitamin K exists as phylloquinone (K1) from plants and menaquinone (K2) from bacterial synthesis.

Explainer

Vitamin K's biochemical role is narrow but indispensable: it is the cofactor required for gamma-carboxylation, a post-translational modification that adds a carboxyl group to specific glutamic acid residues in target proteins. You've seen post-translational modifications before in the context of protein synthesis — the idea that a protein's final functional form differs from its initial translation product. Here, the modification is essential for calcium binding. Without carboxylation, the target proteins cannot coordinate calcium ions, and two critical systems — coagulation and bone mineralization — are compromised simultaneously.

The coagulation cascade, which you studied as a prerequisite, depends on clotting factors activating one another on phospholipid surfaces in the presence of calcium. Four of these factors (II, VII, IX, X) plus the regulatory proteins C and S require gamma-carboxylation to bind calcium and dock onto membrane surfaces. Without functional vitamin K, these proteins are produced as inactive precursors called PIVKA (Proteins Induced by Vitamin K Absence or Antagonism) — they circulate but cannot bind calcium and therefore cannot participate in the cascade. This is precisely the mechanism exploited by warfarin and other vitamin K antagonists, which block the recycling of vitamin K epoxide back to its active form, depleting the cofactor and preventing new carboxylation.

Bone mineralization involves the same chemistry in different proteins. Osteocalcin, synthesized by osteoblasts, requires carboxylation to bind hydroxyapatite crystal surfaces in bone matrix. Matrix Gla protein (MGP), found in vascular smooth muscle and cartilage, requires carboxylation to actively inhibit vascular calcification — undercarboxylated MGP is associated with arterial calcium deposition. This explains why low vitamin K status is associated not just with impaired coagulation but also with reduced bone mineral density and increased arterial stiffness. The two forms of vitamin K — phylloquinone (K1, from leafy greens, preferentially supporting hepatic clotting factor carboxylation) and menaquinones (K2, from fermented foods and gut bacteria, potentially favoring extrahepatic tissues like bone and vasculature) — may have tissue-specific effects, though the clinical significance of this distinction remains under active investigation.